Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dabrafenib and its potential for the treatment of metastatic melanoma
Rajmohan Murali, Alexander M. Menzies, Georgina V. Long
Drug Design Development and Therapy (2012), pp. 391-391
Open Access | Times Cited: 143

Showing 26-50 of 143 citing articles:

Current Insights into Combination Therapies with MAPK Inhibitors and Immune Checkpoint Blockade
Min Hwa Shin, Jiyoung Kim, Siyoung A. Lim, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 7, pp. 2531-2531
Open Access | Times Cited: 67
Distinct Molecular Profiles and Immunotherapy Treatment Outcomes of V600E and V600K BRAF-Mutant Melanoma
Inês Pires da Silva, Kevin Wang, James S. Wilmott, et al.
Clinical Cancer Research (2019) Vol. 25, Iss. 4, pp. 1272-1279
Open Access | Times Cited: 61
FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021
Aleksandra Sochacka-Ćwikła, Marcin Mą̨czyński, Andrzej Regiec
Molecules (2022) Vol. 27, Iss. 7, pp. 2259-2259
Open Access | Times Cited: 31
Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the ‘NSCLC’ of GI Oncology?
Amol Gupta, Razelle Kurzrock, Jacob J. Adashek
Cancers (2023) Vol. 15, Iss. 5, pp. 1578-1578
Open Access | Times Cited: 16
KSR1 knockout mouse model demonstrates MAPK pathway's key role in cisplatin- and noise-induced hearing loss
Matthew A. Ingersoll, Richard D. Lutze, Regina G. Kelmann, et al.
Journal of Neuroscience (2024), pp. e2174232024-e2174232024
Open Access | Times Cited: 6
What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment
Enrico Bronte, Giuseppe Bronte, Giuseppina Novo, et al.
Oncotarget (2015) Vol. 6, Iss. 34, pp. 35589-35601
Open Access | Times Cited: 58
Severe bilateral panuveitis during melanoma treatment by Dabrafenib and Trametinib
D. Draganova, Joseph Kerger, Laure Caspers, et al.
Journal of Ophthalmic Inflammation and Infection (2015) Vol. 5, Iss. 1
Open Access | Times Cited: 57
Genetic Mutations and Epigenetic Modifications: Driving Cancer and Informing Precision Medicine
Krysta M. Coyle, Jeanette E. Boudreau, Paola Marcato
BioMed Research International (2017) Vol. 2017, pp. 1-18
Open Access | Times Cited: 55
Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics
Sadakatsu Ikeda, Jordan S. Lim, Razelle Kurzrock
Molecular Cancer Therapeutics (2018) Vol. 17, Iss. 5, pp. 1114-1122
Open Access | Times Cited: 55
Androgen receptor promotes melanoma metastasis via altering the miRNA-539-3p/USP13/MITF/AXL signals
Yongjun Wang, Zhenyu Ou, Yin Sun, et al.
Oncogene (2016) Vol. 36, Iss. 12, pp. 1644-1654
Closed Access | Times Cited: 53
Designing of kinase hinge binders: A medicinal chemistry perspective
Vikas Sharma, Mohit Gupta
Chemical Biology & Drug Design (2022) Vol. 100, Iss. 6, pp. 968-980
Closed Access | Times Cited: 23
New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study
Mariam M. Fakhry, Amr A. Mattar, Marwa Alsulaimany, et al.
Molecules (2023) Vol. 28, Iss. 21, pp. 7455-7455
Open Access | Times Cited: 15
Clonal differences underlie variable responses to sequential and prolonged treatment
Dylan L. Schaff, Aria J. Fasse, Phoebe E. White, et al.
Cell Systems (2024) Vol. 15, Iss. 3, pp. 213-226.e9
Open Access | Times Cited: 5
Targeted therapy-induced diarrhea: A review of the literature
M.A. Pessi, Nicoletta Zilembo, Eva Regina Haspinger, et al.
Critical Reviews in Oncology/Hematology (2013) Vol. 90, Iss. 2, pp. 165-179
Closed Access | Times Cited: 54
Incidence and characteristics of melanoma brain metastases developing during treatment with vemurafenib
L. Peuvrel, M. Saint‐Jean, G. Quéreux, et al.
Journal of Neuro-Oncology (2014) Vol. 120, Iss. 1, pp. 147-154
Closed Access | Times Cited: 46
Single-agent dabrafenib for BRAF V600E -mutated histiocytosis
Ankush Bhatia, Gary A. Ulaner, Raajit K. Rampal, et al.
Haematologica (2018) Vol. 103, Iss. 4, pp. e177-e180
Open Access | Times Cited: 46
Newly diagnosed papillary craniopharyngioma with BRAF V600E mutation treated with single-agent selective BRAF inhibitor dabrafenib: a case report
Mayank Rao, Meenakshi Bhattacharjee, Scott Shepard, et al.
Oncotarget (2019) Vol. 10, Iss. 57, pp. 6038-6042
Open Access | Times Cited: 36
Uveitis as a Result of MAP Kinase Pathway Inhibition
Lavnish Joshi, Andreas Karydis, Maria Gemenetzi, et al.
Case Reports in Ophthalmology (2013) Vol. 4, Iss. 3, pp. 279-282
Open Access | Times Cited: 42
Innovative Therapeutic Strategies in the Treatment of Brain Metastases
Maria Caffo, Valeria Barresi, Gerardo Caruso, et al.
International Journal of Molecular Sciences (2013) Vol. 14, Iss. 1, pp. 2135-2174
Open Access | Times Cited: 42
Dabrafenib Therapy for Advanced Melanoma
Van Anh Trinh, Jennifer Davis, Jaime Anderson, et al.
Annals of Pharmacotherapy (2013) Vol. 48, Iss. 4, pp. 519-529
Closed Access | Times Cited: 38
Dabrafenib and its use in the Treatment of Metastatic Melanoma
Samantha Bowyer, Rebecca Lee, Alberto Fusi, et al.
Melanoma Management (2015) Vol. 2, Iss. 3, pp. 199-208
Open Access | Times Cited: 38
Competitive allele-specific TaqMan PCR (Cast-PCR) is a sensitive, specific and fast method for BRAF V600 mutation detection in Melanoma patients
Raffaela Barbano, Barbara Pasculli, Michelina Coco, et al.
Scientific Reports (2015) Vol. 5, Iss. 1
Open Access | Times Cited: 37
Melanoma cells resistant towards MAPK inhibitors exhibit reduced TAp73 expression mediating enhanced sensitivity to platinum-based drugs
Elena Makino, Vanessa Gutmann, Corinna Kosnopfel, et al.
Cell Death and Disease (2018) Vol. 9, Iss. 9
Open Access | Times Cited: 35
Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells
Christiane Margue, Demetra Philippidou, Ines Kozar, et al.
Journal of Experimental & Clinical Cancer Research (2019) Vol. 38, Iss. 1
Open Access | Times Cited: 33
A case of recurrent bilateral uveitis independently associated with dabrafenib and pembrolizumab therapy
Stanford Taylor, Frank N. Hrisomalos, Gerald P. Linette, et al.
American Journal of Ophthalmology Case Reports (2016) Vol. 2, pp. 23-25
Open Access | Times Cited: 32

Scroll to top